Drug intelligence / Profile preview

atilotrelvir

Development stage: Phase 3
Lead developer: Fujian Akeylink Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

Atilotrelvir (GST-HG171) is an oral small-molecule inhibitor of the SARS-CoV-2 3C-like protease (3CLpro), also known as the main protease (Mpro). Developed by Fujian Akeylink Biotechnology Co., Ltd., it is designed to treat mild to moderate COVID-19 by blocking the cleavage of viral polyproteins, a step essential for viral replication. In clinical use, atilotrelvir is typically administered in combination with ritonavir, which acts as a pharmacokinetic enhancer by inhibiting the CYP3A enzyme. The drug, marketed under the brand name Taizhongding in China, received conditional approval from the National Medical Products Administration (NMPA) in November 2023 based on clinical trials showing reduced recovery time and efficacy against multiple SARS-CoV-2 variants, including XBB.

Brand names: Taizhongding泰中定
Other names: atilotrelvir

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on atilotrelvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atilotrelvir.

Explore the full profile